Pliant Therapeutics rises as lung disease drug succeeds in mid-stage study

Pliant Therapeutics

14/05/2024 15:46

** Shares of Pliant Therapeutics  PLRX.O  rise 1.7% to
$13.90
    ** Co's experimental idiopathic pulmonary fibrosis (IPF)
drug shows reduction of protein linked to progression of the
disease in patients' lungs during mid-stage study
    ** The drug, bexotegrast, also shows improvement in cough
severity
    ** IPF is the most common type of pulmonary fibrosis, a
disease that causes scarring of lungs
    ** Co says data suggests potential reversal of scarring
    ** YTD, stock down 22.6%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))